Redeye interviews CEO Göran Forsberg about Cantargia's expanded clinical pipeline and start of treatment in second program, CAN10, for autoimmune diseases
Watch the interview hereRedeye interviews CEO Göran Forsberg about the positive announcement that protection for nadunolimab and several variant antibodies remains after oppositions against one of Cantargia's patents
Watch the interview here
(R) = Regulatory press releases
CONTACT US
Cantargia AB
Scheelevägen 27
SE-223 63 Lund, Sweden
E-mail: info@cantargia.com
Switch board: +46(0)46 2756260
Privacy Policy